Total assets have contracted significantly from $230.6M in 2024Q2 to $107.8M in 2026Q1, as cumulative losses have driven retained earnings to a deficit of $293.9M.
| Total Current Assets | 99.22M | 120.44M | 181.63M | 129.69M | 132.09M | 100.41M | 1.72M |
| Cash & Short-Term Investments | 97.74M | 118.58M | 179.48M | 127.46M | 127.75M | 99.6M | 1.58M |
| Cash Only | 34.06M | 41.5M | 39.82M | 36.02M | 29.52M | 99.6M | 1.58M |
| Short-Term Investments | 63.67M | 77.08M | 139.66M | 91.44M | 98.23M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 1.48M | 1.86M | 2.15M | 2.23M | 4.34M | 0 | 0 |
| Total Non-Current Assets | 8.61M | 9.27M | 14.96M | 8.57M | 49.13M | 6.18M | 466K |
| Property, Plant & Equipment | 6.91M | 7.42M | 8.03M | 7.91M | 6.86M | 5.79M | 59K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 15.31M | 0 | 5.09M | 0 | 41.88M | 0 | 0 |
| Other Non-Current Assets | 1.7M | 1.86M | 1.84M | 665K | 388K | 388K | 407K |
| Total Assets | 107.83M | 129.72M | 196.59M | 138.26M | 181.23M | 106.59M | 2.19M |
| Asset Turnover | 0.00x | - | - | - | - | - | - |
| Asset Growth % | -136.41% | -34.02% | 42.18% | -23.71% | 70.03% | 4778.12% | - |
| Total Current Liabilities | 11.05M | 15.66M | 17.21M | 13.3M | 6.52M | 2.91M | 613K |
| Accounts Payable | 1.16M | 2.28M | 758K | 5.05M | 904K | 964K | 136K |
| Days Payables Outstanding | -2.24K | 612.91 | 275.02 | 3.44K | - | - | 3.82K |
| Short-Term Debt | 1.15M | 0 | 1.06M | 0 | 0 | 0 | 58K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 69K | 66K | 0 |
| Other Current Liabilities | 8.74M | 5.56M | 5.46M | 3.86M | 2.66M | 667K | 334K |
| Current Ratio | 8.98x | 7.69x | 10.55x | 9.75x | 20.27x | 34.46x | 2.80x |
| Quick Ratio | 8.98x | 7.69x | 10.55x | 9.75x | 20.27x | 34.46x | 2.80x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.26M | 1.54M | 2.59M | 3.77M | 4.24M | 127.48M | 9.98M |
| Long-Term Debt | 1.26M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 3.65M | 1.54M | 2.59M | 3.77M | 4.24M | 4.96M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 122.52M | 9.98M |
| Total Liabilities | 12.32M | 17.2M | 19.8M | 17.07M | 10.75M | 130.4M | 10.6M |
| Total Debt | 2.42M | 2.71M | 3.65M | 4.64M | 4.96M | 5.63M | 58K |
| Net Debt | -31.65M | -38.79M | -36.17M | -31.37M | -24.56M | -93.97M | -1.52M |
| Debt / Equity | 0.03x | 0.02x | 0.02x | 0.04x | 0.03x | - | - |
| Debt / EBITDA | -0.03x | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.38x | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | 95.52M | 112.52M | 176.79M | 121.19M | 170.47M | -23.81M | -8.41M |
| Equity Growth % | -145.28% | -36.35% | 45.87% | -28.91% | 816.01% | -183% | - |
| Book Value per Share | 2.47 | 2.92 | 4.62 | 5.49 | 7.78 | -1.84 | -0.65 |
| Total Shareholders' Equity | 95.52M | 112.52M | 176.79M | 121.19M | 170.47M | -23.81M | -8.41M |
| Common Stock | 38K | 31K | 31K | 23K | 22K | 2K | 1K |
| Retained Earnings | -293.92M | -274.88M | -196.98M | -116.42M | -56.03M | -24.86M | -8.62M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4K | 111K | 447K | -83K | -95K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial execution failure
Based on reported financial statements, Acrivon's total assets have contracted from $230.6M in 2024Q2 to $107.8M by 2026Q1, reflecting a consistent depletion of resources as the company funds its non-discretionary R&D pipeline and clinical trial infrastructure without the benefit of commercial revenue streams.
The downward trajectory in total assets suggests that the company is consuming its capital base to sustain its proteomic platform development. Investors should monitor whether the current asset base remains sufficient to reach critical data readouts without necessitating further dilutive financing events.
As reported in quarterly filings, the company's cash position has fluctuated significantly, reaching $34.1M in 2026Q1, while maintaining a current ratio of 8.98, which indicates that while short-term obligations are covered, the firm remains highly dependent on external capital to maintain its operational runway.
The high current ratio is a function of low current liabilities rather than an abundance of cash, highlighting the company's lean operating structure. This liquidity profile appears adequate for near-term clinical milestones, but the persistent cash burn warrants caution regarding the timing of future capital raises.
According to the provided balance sheet data, retained earnings have deteriorated to -$293.9M as of 2026Q1, illustrating the cumulative impact of heavy R&D investment and the absence of commercial revenue on the company's total equity base over the last ten quarters.
The consistent decline in equity highlights the high cost of advancing the AP3 platform and ACR-368 through clinical stages. This trend suggests that shareholder value is currently being prioritized toward long-term clinical proof-of-concept rather than near-term balance sheet preservation.
Based on the reported figures, the company's asset base is almost entirely devoid of goodwill or significant tangible assets, with net PPE of only $6.9M in 2026Q1, which implies that the firm's value is almost exclusively tied to intangible intellectual property and clinical trial progress.
The lack of tangible assets makes the company's valuation highly sensitive to clinical trial outcomes, as there is little residual value to support the balance sheet in the event of a failure. This asset-light structure is typical for early-stage biotech but underscores the binary nature of the investment risk.
Quick answers to the most common questions about buying ACRV stock.
As of 2025, Acrivon Therapeutics, Inc. Common Stock (ACRV) had total assets of $129.7M including $120.4M in current assets.
Acrivon Therapeutics, Inc. Common Stock (ACRV) carries total debt of $2.7M, offset by $118.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Acrivon Therapeutics, Inc. Common Stock (ACRV) has total shareholders' equity (book value) of $112.5M ($2.92 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Acrivon Therapeutics, Inc. Common Stock (ACRV) reported a current ratio of 7.69x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.